Catheter Precision, Inc. (NYSE American: VTAK) has announced its financial results for the fourth quarter and full year ended December 31, 2025, showcasing a remarkable 95% increase in revenue year-over-year, reaching $819 thousand compared to $420 thousand in 2024. The company has achieved significant clinical, commercial, and regulatory milestones, including the receipt of CE Mark for its LockeT device and the first commercial sales in Europe. CEO David A. Jenkins expressed satisfaction with the company's progress, highlighting the expansion of their customer base and the advancement of their product lines, VIVO and LockeT. The company also announced the acquisition of Flyte, a regional air mobility company, which is expected to diversify its operations and enhance growth potential. This strategic move positions Catheter Precision to capitalize on both healthcare technology and aviation markets, with multiple catalysts for growth anticipated in the near future. The financial highlights for 2025 include a gross margin of 92.3%, up from 90.0% in 2024, although the company reported a net loss of $17.2 million, slightly higher than the previous year's loss of $16.6 million. The company is optimistic about its strategic outlook for 2026, aiming to leverage its strengthened capital resources and differentiated growth platforms to unlock shareholder value.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.